» Articles » PMID: 36405870

Cognitive Processes of Apathy in Huntington's Disease Show High Sensitivity to Disease Progression

Overview
Date 2022 Nov 21
PMID 36405870
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Disease-modifying treatments for Huntington's disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD.

Objective: Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD.

Methods: 83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up.

Results: The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score).

Conclusion: The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.

References
1.
Ang Y, Manohar S, Plant O, Kienast A, Le Heron C, Muhammed K . Dopamine Modulates Option Generation for Behavior. Curr Biol. 2018; 28(10):1561-1569.e3. PMC: 5981001. DOI: 10.1016/j.cub.2018.03.069. View

2.
McLauchlan D, Lancaster T, Craufurd D, Linden D, Rosser A . Insensitivity to loss predicts apathy in huntington's disease. Mov Disord. 2019; 34(9):1381-1391. DOI: 10.1002/mds.27787. View

3.
Tabrizi S, Scahill R, Owen G, Durr A, Leavitt B, Roos R . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013; 12(7):637-49. DOI: 10.1016/S1474-4422(13)70088-7. View

4.
Callaghan J, Stopford C, Arran N, Boisse M, Coleman A, Santos R . Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci. 2015; 27(1):59-64. DOI: 10.1176/appi.neuropsych.13070169. View

5.
Lunven M, Bagnou J, Youssov K, Gabadinho A, Fliss R, Montillot J . Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT). PLoS One. 2021; 16(8):e0253064. PMC: 8382187. DOI: 10.1371/journal.pone.0253064. View